Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.45 USD
+0.01 (0.05%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.45 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth D Momentum A VGM
Zacks News
Allergan's Botox Gets FDA Nod for Forehead Line Treatment
by Zacks Equity Research
Allergan (AGN) secures an FDA approval for Botox Cosmetic product for its third indication of forehead line development.
Allergan (AGN) Pipeline & New Drugs to Counter Generic Woes
by Zacks Equity Research
Allergan's key drugs like Botox/Linzess and new drugs are supporting sales. However, Allergan faces generic threat for Namenda franchise and patent challenges for some other branded drugs.
Teva Reintroduces Generic Depo-Provera Injection in U.S.
by Zacks Equity Research
Teva (TEVA) announced the reintroduction of the generic equivalent to Depo-Prover Contraceptive Injection 150 mg/mL in the United States.
Impax Generic Division Progresses Well Amid Pricing Pressure
by Zacks Equity Research
Impax Laboratories' (IPXL) generic portfolio has progressed well so far this year. Moreover, approval of the generic versions of Vytorin and Concerta is a positive.
Allergan Authorizes New $2B Share Buyback Plan, Stock Up
by Zacks Equity Research
Allergan plc (AZN) sanctions a new stock repurchase program. The company also reiterates its commitment toward annual hike of quarterly cash dividend.
Teva/Nuvelution to Speed Up Development of Austedo in US
by Zacks Equity Research
Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.
Teva's Leukemia Drug sNDA Granted Priority Review by the FDA
by Zacks Equity Research
Teva Pharmaceutical's (TEVA) sNDA for label expansion of Trisenox as first-line treatment of acute promyelocytic leukemia has been accepted by the FDA under priority review.
Company News For Sep 13, 2017
by Zacks Equity Research
Companies in the news are: TEVA,WDC,AMZN,LMNR
Teva's New CEO Brings No Relief: Generic Drugmakers to Dump
by Zacks Equity Research
The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.
Company News For Sep 12, 2017
by Zacks Equity Research
Companies in the news are: TEVA,BMY,EFX,FB
Cooper Companies Buys Teva's PARAGARD Intrauterine Platform
by Zacks Equity Research
Cooper Companies (COO) latest development is expected to fortify its foothold in the contraceptive device market. Margins are likely to improve within one year of the deal closure.
Why Did Teva Pharmaceuticals Stock Soar Today?
by Ryan McQueeney
Shares of Teva Pharmaceuticals (TEVA) opened more than 15% higher on Monday after the struggling drugmaker picked H. Lundbeck (HLUYY) chief Kare Schultz to fill its long-vacant CEO role.
Teva Hires Kare Schultz as CEO: Is a Recovery in the Cards?
by Zacks Equity Research
Teva Pharmaceutical (TEVA) announced the appointment of H. Lundbeck's Kare Schultz as President and Chief Executive Officer (CEO).
Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) announced promising data from a phase IIb study on tezepelumab, which reduced the rate of deterioration of asthma in patients with severe uncontrolled asthma.
Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study
by Zacks Equity Research
Novartis AG (NVS) announced positive top-line results from the phase III study, PARADIGMS on MS Drug Gilenya for children and adolescents.
Teva Austedo Gets FDA Nod for Label Expansion in Dyskinesia
by Zacks Equity Research
Teva Pharmaceutical (TEVA) announced that the FDA has approved the label expansion of Austedo to include tardive dyskinesia in adults. Shares are up since announcement.
Impax Laboratories (IPXL) Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
Impax Laboratories (IPXL) reported positive second-quarter results with earnings and sales both beating estimates. The company has strengthened its generic portfolio with additional approvals during the quarter.
SolarEdge (SEDG) and Teva (TEVA) are Blowouts!
by Brian Bolan
One stock is being blown off the books and one had a blow out earnings report.
Teva Plunges to 10-Year Low, Credit Rating in Jeopardy
by Ryan McQueeney
Shares of Teva Pharmaceuticals (TEVA), a favorite for investors chasing large dividend yields, fell more than 4.4%--and hit a 10-year intraday low--on Wednesday.
VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y
by Zacks Equity Research
VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.
Generic Drug Stocks Take a Hit: Here's Why
by Arpita Dutt
As generic drug pricing concerns loom large, Teva (TEVA) and other players in the generic market saw their shares tumble last week.
Teva Q2 Earnings Lag, '17 View & Dividend Cut, Stock Slumps
by Zacks Equity Research
Teva Pharmaceutical Industries Limited's (TEVA) Q2 earnings and missed expectations. It also slashed its 2017 earnings and sales outlook and cut its dividend by 75%.
Allergan (AGN) Q2 Earnings & Sales Top, Restasis Sales Down
by Zacks Equity Research
Allergan plc (AGN) beat estimates for both earnings and sales in Q2. The company raised its 2017 outlook. Shares were down slightly in pre-market trading.
Teva (TEVA) Q2 Earnings and Sales Miss, Shares Down
by Zacks Equity Research
Teva Pharmaceutical (TEVA) second quarter earnings and revenue missed estimates. The company has also lowered its earnings and revenue guidance for 2017.
What's in Store for Arena (ARNA) this Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.